Application Detail
Description of Medical Service
Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.Description of Medical Condition
Diffuse Large B-Cell Lymphoma is an aggressive and common subtype of Non-Hodgkin Lymphoma.Reason for Application
Request to amend the eligibility criteria to remove the requirement for patients to be “CD19-positive”.Medical Service Type
Hybrid health technologyPrevious Application Number/s
15191519.1
Associated Documentation
Public Summary Document
Public Summary Document (PDF 318 KB)Public Summary Document (Word 73 KB)